Sphincter of Oddi dysfunction (SOD) is impaired biliary or pancreatic duct drainage due to abnormal function of the sphincter mechanism at the ampulla of Vater. It is a diagnosis of exclusion — made after organic cause (stone, stricture, tumor) is ruled out. Develops in 10-20% of postcholecystectomy patients and is an important cause of postcholecystectomy syndrome. Classified by Milwaukee classification: Type I (structural — dilated duct + abnormal enzymes + pain), Type II (suspicious — one or two criteria), Type III (functional — pain only). Sphincter manometry is gold standard for diagnosis but is invasive with complication risk (2-5% pancreatitis). In imaging, bile duct dilatation is variable — prominent in SOD Type I, usually normal in Type III. MRCP and HIDA scintigraphy provide supportive findings; the primary role of imaging is to exclude organic obstruction.
Age Range
30-65
Peak Age
45
Gender
Female predominant
Prevalence
Uncommon
The sphincter of Oddi is a complex sphincter mechanism consisting of smooth muscle at the point where CBD and pancreatic duct open into duodenum. It comprises three separate sphincter components: sphincter choledochus, sphincter pancreaticus, and sphincter ampullae. In normal function, it regulates bile and pancreatic fluid flow through basal tone (3-35 mmHg) and rhythmic phasic contractions (3-10/min). Two fundamental mechanisms are involved in SOD: (1) sphincter stenosis (structural — recurrent pancreatitis, papillitis, fibrosis, adenomyosis, or chronic inflammation from previous stone passage) or (2) sphincter dyskinesia (functional — smooth muscle spasm, dysmotility, neurogenic dysregulation). In stenosis type, sphincter basal pressure rises >40 mmHg and bile flow is chronically impaired — upstream biliary dilatation and intermittent pain develop. In dyskinesia type, basal pressure may be normal but paradoxical contractions (contraction instead of expected relaxation in response to CCK) or impaired sphincter relaxation exist. In imaging, the sphincter cannot be directly evaluated structurally — indirect findings are used: mild CBD dilatation (>8 mm postcholecystectomy) on MRCP, delayed bowel transit (>60 min) on HIDA scintigraphy, pancreatic duct response evaluation on secretin-MRCP. The EPISOD trial showed sphincterotomy is not superior to placebo in SOD Type III and has changed current management approach.
Radiopharmaceutical transit to bowel exceeding >60 minutes on HIDA — most reliable non-invasive indicator of sphincter dysfunction.
CBD diameter >8 mm on MRCP (postcholecystectomy norm 6-8 mm) but no stone, stricture, or mass detected at distal CBD. Duct walls are smooth without thickening. Intrahepatic ducts may be normal or mildly dilated. Greatest value of MRCP is excluding organic obstructive causes — confirming absence of stone, stricture, tumor. On secretin-MRCP, change in pancreatic duct diameter indirectly evaluates sphincter function.
Report Sentence
CBD dilatation on MRCP without stone, stricture, or mass; SOD should be considered in differential diagnosis.
Normal liver uptake but delayed radiopharmaceutical transit to bowel (>60 minutes) on HIDA scintigraphy. CCK-provocation HIDA showing gallbladder ejection fraction <35% (precholecystectomy) or prolonged hilum-duodenum transit time (postcholecystectomy) supports SOD. Morphine-augmented HIDA provokes sphincter spasm and duct dilatation — positive in SOD.
Report Sentence
Delayed radiopharmaceutical transit to bowel (>60 min) on HIDA scintigraphy may be consistent with SOD.
Borderline increased CBD diameter (6-10 mm postcholecystectomy) on US but no stone or mass seen. On dynamic US, paradoxical increase in CBD diameter after fatty meal may support SOD (normal: diameter decreases). Gallbladder absent (postcholecystectomy).
Report Sentence
Borderline increased CBD diameter without stone or mass; SOD should be evaluated in differential diagnosis.
NO diffusion restriction at ampullary region on DWI — helpful in excluding malignant obstruction (adenocarcinoma). SOD is a functional disorder and does not create structural lesion. Presence of solid mass at ampullary region excludes SOD diagnosis.
Report Sentence
No diffusion restriction or mass at ampullary region on DWI.
On secretin-MRCP, expected transient increase in pancreatic duct diameter after secretin injection does not occur or excessive expansion (>3 mm increase persists) indicates sphincter dysfunction. In normal response, duct transiently widens in 5-10 minutes then returns to baseline diameter. In SOD, duct widening persists because sphincter does not allow adequate drainage.
Report Sentence
Prolonged pancreatic duct widening on secretin-MRCP consistent with sphincter dysfunction.
Criteria
Dilated CBD (>12 mm) + abnormal ALP/AST (>2×normal) + biliary-type pain
Distinct Features
ERCP sphincterotomy >90% successful; manometry may not be needed
Criteria
One or two criteria positive (dilatation OR enzyme elevation) + pain
Distinct Features
Manometry recommended; sphincterotomy 50-60% successful
Criteria
Biliary-type pain only; normal duct diameter and normal enzymes
Distinct Features
Sphincterotomy ineffective (10-20%); medical therapy (nifedipine, trimebutine) preferred; EPISOD trial negative
Distinguishing Feature
Choledocholithiasis shows filling defect on MRCP; SOD has no stone, only functional dilatation
Distinguishing Feature
Benign stricture shows focal duct narrowing on MRCP; SOD has no duct narrowing
Distinguishing Feature
Ampullary adenoma shows solid lesion at ampulla on CT/MR; SOD has no structural lesion
Urgency
routineManagement
medicalBiopsy
Not NeededFollow-up
6-monthIn SOD Type I, ERCP sphincterotomy is first-line treatment (>90% success rate) — manometry may not be needed as clinical and imaging findings are sufficient. In Type II, sphincterotomy decision is based on manometry result — sphincterotomy is 50-60% successful if basal pressure >40 mmHg. In Type III, EPISOD trial (randomized, sham-controlled) showed sphincterotomy is not superior to placebo — medical therapy (calcium channel blockers — nifedipine 10-20 mg/day, anticholinergics, trimebutine, neuromodulators — amitriptyline) is preferred. The primary role of imaging is excluding organic obstruction (stone, stricture, tumor) — therefore MRCP should be performed in all patients with suspected SOD. HIDA scintigraphy is helpful for functional assessment but is not diagnostic alone.
SOD is a diagnosis of exclusion — choledocholithiasis, bile duct stricture, and pancreatitis must be ruled out first. The Milwaukee classification system (Type I, II, III) determines the treatment approach. Type I has a high success rate with endoscopic sphincterotomy (90%+). Diagnosis and treatment of Type III is more controversial.